Inhaled corticosteroids are anti-inflammatory medications that can down-regulate the immunologic response in patients with COPD; however, their role at onset of COPD exacerbation is still not understood. The aim of this study was to assess the early inflammatory response and clinical presentation of patients with COPD exacerbation mediated by inhaled corticosteroids.
METHODS:
Prospective data were collected on 123 hospitalized subjects with COPD exacerbation over a 30-month period at 2 Spanish university hospitals. Based on domiciliary use, comparative analyses were performed between subjects who did not use inhaled corticosteroids (n = 58) and subjects who did (n = 65). Measurements of serum biomarkers were recorded on admission to the hospital (day 1) and on day 3; clinical, physiological, microbiological, and severity data and mortality/readmission rates were also recorded.
RESULTS:
At days 1 and 3, both groups showed a similar inflammatory response; fluticasone produced lower levels of interleukin-8 compared with budesonide (P < .01). All clinical features considered were similar in the 2 groups; multivariate analysis predicting clinical complications on hospitalization showed air-flow obstruction severity as the only predictive factor (odds ratio 3.13, 95% CI 1.13–8.63, P = .02).
CONCLUSIONS:
Our study demonstrates a lack of inhaled corticosteroid influence in the early systemic inflammatory response to and clinical presentation of COPD exacerbation.
AnthonisenNR, ManfredaJ, WarrenCP, HershfieldES, HardingGK, NelsonNA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987; 106(2):196–204.
3.
SullivanSD, RamseySD, LeeTA. The economic burden of COPD. Chest, 2000; 117(2 Suppl):5S–9S.
4.
DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002; 57(10):847–852.
5.
SeemungalTA, DonaldsonGC, PaulEA, BestallJC, JeffriesDJ, WedzichaJA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998; 157(5 Pt 1):1418–1422.
6.
Soler-CataluñaJJ, Martínez-GarcíaMA, Román SánchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 2005; 60(11):925–931.
7.
PapiA, BellettatoCM, BraccioniF, RomagnoliM, CasolariP, CaramoriG, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 2006; 173(10):1114–1121.
8.
Di StefanoA, TuratoG, MaestrelliP, MappCE, RuggieriMP, RoggeriA, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med, 1996; 153(2):629–632.
9.
HurstJR, PereraWR, WilkinsonTM, DonaldsonGC, WedzichaJA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006; 173(1):71–78.
10.
KoutsokeraA, StolzD, LoukidesS, KostikasK. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest, 2012; 141(2):396–405.
11.
PereraWR, HurstJR, WilkinsonTM, SapsfordRJ, MüllerovaH, DonaldsonGC, WedzichaJA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J, 2007; 29(3):527–534.
12.
SinDD, LacyP, YorkE, ManSF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004; 170(7):760–765.
13.
CalverleyPMA, BarnesPJ. Pro/con editorials: inhaled corticosteroids are/are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2000; 161(2 Pt 1):341–344.
14.
ChenD, RestrepoMI, FineMJ, PughMJ, AnzuetoA, MeterskyML, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med, 2011; 184(3):312–316.
15.
SellaresJ, López-GiraldoA, LucenaC, CillonizC, AmaroR, PolverinoE, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med, 2013; 187(11):1241–1248.
16.
BurgePS, CalverleyPM, JonesPW, SpencerS, AndersonJA, MaslenTK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ, 2000; 320(7245):1297–303.
17.
VestboJ, SørensenT, LangeP, BrixA, TorreP, ViskumK. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 1999; 353(9167):1819–1823.
18.
SinghS, AminAV, LokeYK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med, 2009; 169(3):219–229.
19.
DrummondMB, DasenbrookEC, PitzMW, MurphyDJ, FanE. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 2008; 300(20):2407–2416.
20.
SuissaS, PatenaudeV, LapiF, ErnstP. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax, 2013; 68(11):1029–1036.
21.
QuanjerPH, TammelingGJ, CotesJE, PedersenOF, PeslinR, YernaultJC. Lung volumes and forced ventilatory flows: report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl, 1993; 16:5–40.
22.
SorianoJB, SinDD, ZhangX, CampPG, AndersonJA, AnthonisenNR, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest, 2007; 131(3):682–689.
23.
CulpittSV, RogersDF, ShahP, De MatosC, RussellRE, DonnellyLE, BarnesPJ. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2003; 167(1):24–31.
24.
HattotuwaKL, GizyckiMJ, AnsariTW, JefferyPK, BarnesNC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med, 2002; 165(12):1592–1596.
25.
LoppowD, SchleissMB, KanniessF, TaubeC, JörresRA, MagnussenH. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med, 2001; 95(2):115–121.
26.
ItoK, BarnesPJ, AdcockIM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol, 2000; 20(18):6891–903.
27.
BarnesPJ, ItoK, AdcockIM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet, 2004; 363(9410):731–733.
28.
ItoK, ItoM, ElliottWM, CosioB, CaramoriG, KonOM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med, 2005; 352(19):1967–1976.
29.
EkA, LarssonK, SiljerudS, PalmbergL. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy, 1999; 54(7):691–699.
30.
WilsonR, JonesP, SchabergT, ArvisP, Duprat-LomonI, SagnierPP, MOSAIC Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax, 2006; 61(4):337–342.
31.
DewanNA, RafiqueS, KanwarB, SatpathyH, RyschonK, TillotsonGS, NiedermanMS. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest, 2000; 117(3):662–671.
32.
AlmagroP, CabreraFJ, DiezJ, BoixedaR, Alonso OrtizMB, MurioC, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de Medicina Interna (ESMI) study. Chest, 2012; 142(5):1126–1133.
33.
AgustíA, EdwardsLD, RennardSI, MacNeeW, Tal-SingerR, MillerBE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE, 2012; 7(5):e37483.
34.
BafadhelM, McKennaS, TerryS, MistryV, ReidC, HaldarP, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med, 2011; 184(6):662–671.
35.
BafadhelM, McKennaS, TerryS, MistryV, PancholiM, VengeP, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med, 2012; 186(1):48–55.
